Australia’s CSL to Invest $1.5 Billion in US Drug Manufacturing

Australia’s largest drugmaker CSL Ltd. is committing roughly $1.5 billion to expand its US manufacturing footprint, joining a wave of pharmaceutical giants doubling down on American production.

The move will expand CSL’s US production capacity for plasma-derived therapies, which are made from donated blood and can treat a range of serious diseases including immune system and bleeding disorders.

“The U.S. is the world’s leading source for plasma, the main component of plasma derived therapies,” Chief Executive Officer and Managing Director Paul McKenzie said in a statement. The company operates more than 300 collection centers across the US.

President Donald ...